Getting a therapeutic gene into the right cell has been one of medicine’s most stubborn problems, especially in the brain and spinal cord. Now, scientists at University College Dublin say they have found that cells already possess a built-in relay system for passing biological cargo from one cell to the next, a discovery published in April 2026 in Nature Materials that could eventually open new routes for gene and RNA therapies.
The study was led by Kenneth Dawson, director of UCD’s Centre for BioNano Interactions. His team discovered that when nanoparticles enter a cell, a small number avoid the usual fate of being broken down by lysosomes, the cell’s recycling machinery. Instead, these nanoparticles pick up a protective shell made of biomolecular condensates, dense, gel-like clusters of proteins and nucleic acids that form spontaneously inside cells through a process called liquid-liquid phase separation. The researchers call this shell a “condensate corona.”
Once coated, the nanoparticles slip past the cell’s defenses, exit through its membrane, and get taken up by neighboring cells with their molecular payload still functional. In effect, the cell acts as a courier, packaging and forwarding the nanoparticle rather than destroying it.
“We were surprised to find that cells have this hidden relay capability,” Dawson said in a statement released by UCD. “The condensate corona essentially gives the nanoparticle a biological disguise that lets it move between cells without being destroyed.”
Why delivery remains gene therapy’s biggest bottleneck
The finding arrives at a moment when the gene therapy field is acutely aware of its delivery limitations. Adeno-associated viruses, or AAVs, remain the workhorse vectors for ferrying genetic material into patients. But AAVs carry significant baggage of their own: they can hold only small genetic payloads, they trigger immune responses that sometimes neutralize them before they reach their target, and they depend on specific receptors on the cell surface that vary from tissue to tissue.
These constraints hit hardest in the central nervous system. Research highlighted by the U.S. National Institutes of Health has documented how AAVs often fail to reach enough neurons or glial cells in the brain and spinal cord to produce a meaningful clinical effect. Even the basic science of how AAVs enter cells is still being mapped: a 2024 study by Mbhatt et al. published in Cell identified a previously unknown alternate AAV receptor known as AAVR2 (also called CPD), underscoring gaps in the field’s understanding of viral delivery at the most fundamental level.
The condensate corona works by a different logic entirely. Instead of requiring a virus to dock with a specific surface receptor, the nanoparticle-condensate complex appears to ride the cell’s own export and import machinery. That distinction is significant because it suggests a non-viral route that could sidestep the immune and receptor-related bottlenecks that constrain AAV-based approaches. To the body, a condensate-coated nanoparticle may look less like an invader and more like routine cellular housekeeping.
What the study does and does not show
The Nature Materials paper provides peer-reviewed, experimentally documented evidence that nanoparticles can acquire a condensate corona, survive lysosomal processing, leave one cell, and enter another with functional cargo. That is a confirmed observation at the cellular level, and it establishes the biological reality of the mechanism.
But several critical gaps separate this lab result from anything resembling a therapy.
First, the pathway is rare. The study describes the condensate corona route as an uncommon trajectory among the many paths a nanoparticle can take inside a cell. The paper does not quantify what fraction of nanoparticles successfully complete the full cycle of corona acquisition, lysosomal evasion, export, and re-entry. Without that efficiency figure, it is impossible to judge whether the mechanism could deliver therapeutic doses to enough cells to treat a disease.
Second, all published evidence comes from cell-based experiments. No animal data have been reported showing that the system works across the blood-brain barrier or within intact tissue. The blood-brain barrier is one of the most formidable obstacles in neurology, and a mechanism that functions between cultured cells in a dish may behave very differently inside a living organism, where immune surveillance, blood flow, and complex tissue architecture all intervene.
Third, no published statements from the research team detail how the condensate corona might integrate with existing delivery platforms, whether AAV vectors, lipid nanoparticles of the kind used in mRNA vaccines, or entirely synthetic carriers. The therapeutic framing offered by UCD’s institutional press release is plausible but remains speculative until those engineering questions are addressed.
Where the science goes from here
Separate research in nanomedicine has confirmed that nanomaterials can interact with and modulate biomolecular condensates through a process called triphasic separation, establishing that the underlying physics of nanoparticle-condensate interactions is reproducible beyond the UCD lab. That lends credibility to the core finding but does not, on its own, validate a drug delivery strategy.
To move from mechanism to medicine, researchers will need to clear several hurdles: demonstrating that condensate coronas can be induced reliably and at scale, proving that the cargo they carry remains intact and biologically active after transfer, and showing that the process works in animal models at doses and time scales compatible with real-world treatment. Safety and toxicity data will also be essential before any human application is considered.
No specific funding announcements tied to the condensate corona discovery have been made public. Without dedicated support from agencies such as the NIH or European research councils, the timeline for animal studies and eventual clinical trials could stretch considerably.
What this means for patients watching the gene therapy field
For the millions of people living with neurological and genetic disorders that current gene therapies cannot adequately reach, the condensate corona is a reason for cautious interest rather than immediate hope. The discovery expands scientists’ understanding of how cells exchange complex molecular cargo and suggests that biology has built-in relay systems that medicine has not yet learned to exploit.
But in the broader arc of gene delivery research, breakthroughs in basic science routinely take years, sometimes decades, to translate into treatments. The condensate corona fits that pattern: a genuinely novel observation that opens conceptual doors while leaving the hard engineering work ahead. As additional studies test this mechanism in more realistic biological settings, the picture will sharpen, either confirming the condensate corona as a viable delivery pathway or revealing it as a fascinating but limited piece of cellular biology.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
